These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 12453859)
1. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Zanotti R; Trolese A; Ambrosetti A; Nadali G; Visco C; Ricetti MM; Benedetti F; Pizzolo G Ann Oncol; 2002 Dec; 13(12):1908-14. PubMed ID: 12453859 [TBL] [Abstract][Full Text] [Related]
2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685 [TBL] [Abstract][Full Text] [Related]
3. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607 [TBL] [Abstract][Full Text] [Related]
5. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
6. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405 [TBL] [Abstract][Full Text] [Related]
8. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171 [TBL] [Abstract][Full Text] [Related]
9. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381 [TBL] [Abstract][Full Text] [Related]
10. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149 [TBL] [Abstract][Full Text] [Related]
11. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718 [TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364 [TBL] [Abstract][Full Text] [Related]
13. Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. van den Berg H; Stuve W; Behrendt H Med Pediatr Oncol; 1997 Jul; 29(1):23-7. PubMed ID: 9142201 [TBL] [Abstract][Full Text] [Related]
14. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease. Ng AK; Li S; Neuberg D; Silver B; Stevenson MA; Fisher DC; Mauch PM Ann Oncol; 2004 Feb; 15(2):270-5. PubMed ID: 14760121 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Diefenbach CS; Li H; Hong F; Gordon LI; Fisher RI; Bartlett NL; Crump M; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ; Advani RH Br J Haematol; 2015 Nov; 171(4):530-8. PubMed ID: 26343802 [TBL] [Abstract][Full Text] [Related]
16. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131 [TBL] [Abstract][Full Text] [Related]
17. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy. Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276 [TBL] [Abstract][Full Text] [Related]
18. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Canellos GP Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509 [TBL] [Abstract][Full Text] [Related]
19. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience. Chim CS; Kwong YL; Lie AK; Lee CK; Ho FC; Liang R Am J Hematol; 1999 Jul; 61(3):159-63. PubMed ID: 10398307 [TBL] [Abstract][Full Text] [Related]
20. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]